Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Open Label, Randomized, Controlled Clinical Study Evaluating the Effect of NovoSorb ® SynPath™ Dermal Matrix Compared to Standard of Care (SOC) In the Treatment of Nonresponsive, Chronic Diabetic Foot Ulcers.
Conditions
Interventions
SynPath Acellular Dermal Matrix plus Off-loading Device
Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device
Locations
7
United States
Center for Clinical Research
Castro Valley, California, United States
Limb Preservation Platform, Inc
Fresno, California, United States
ILD Research Center
Vista, California, United States
Barry University Clinical Research
Tamarac, Florida, United States
Lower Extremity Institute for Research and Therapy, LLC
Youngstown, Ohio, United States
JPS Health Network
Fort Worth, Texas, United States
Start Date
July 10, 2022
Primary Completion Date
February 26, 2024
Completion Date
February 26, 2024
Last Updated
March 5, 2024
NCT06383013
NCT07039396
NCT07396376
NCT07372404
NCT07330154
NCT07200401
Lead Sponsor
PolyNovo Biomaterials Pty Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions